ALK and ovarian carcinoma: In addition, Kanakkanthara et al. noted that the combination of ceritinib and PARP inhibitors enhanced the inhibitory effect of PARP inhibitors on ovarian cancer by taking advantage of the fact that ceritinib, an anaplastic lymphoma kinase (ALK) inhibitor, can induce oxidative stress and promote oxidative DNA damage by increasing ROS [96].